Varian Medical Systems, Inc. (VAR - Analyst Report) received an order for 20 TrueBeam machines from NHS Supply Chain for NHS hospitals across the U.K. The deal shall be facilitated through the capital equipment fund of NHS hospitals, following the government hospital chain’s acknowledgement of the need to modernize its radiotherapy as well as radiosurgery treatments for patients in the U.K.
The new agreement is the continuation of a successful program launched last year, that completed the delivery of ten such TrueBeam systems to radiotherapy departments of oncology centers located in Newcastle, Liverpool, Hull, Sheffield, Guildford, Hereford, Poole, and London.
Varian's TrueBeam system has been integrated with a host of new technical innovations that includes synchronize imaging, patient positioning, motion management and treatment delivery during a radiotherapy or radiosurgery procedure. The new system also features a high dose delivery rate that shortens the treatment time, as compared with the earlier generations of radiotherapy technology. TrueBeam can be successfully used for the treatment of lung, breast, intracranial, prostate, head and neck, and other types of cancer.
NHS hospitals spread across the U.K., will benefit from this order as it will get a chance to replace and modernize its base of 300 linear accelerators (100 of these are more than ten years old) with a more advanced and accurate treatment system.
The agreement to supply such systems reflects the demand for highly competent cancer treatment technology in NHS hospitals. The collaboration between Varian and the UK government is expected to save up to approximately 10,000 lives per year.
Varian also gets the opportunity to assert its long standing commitment towards bringing in new, effective and cost-efficient medical technology, thus fulfilling the growing needs of the modern healthcare industry.
Currently, VAR carries a Zacks Rank #3 (Hold).Other medical stocks that are worth a look include Echo Therapeutics, Inc. , Given Imaging Ltd. , and Luminex Corporation (LMNX - Analyst Report), each carrying a Zacks Rank #2 (Buy).